MX2020002880A - Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). - Google Patents

Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).

Info

Publication number
MX2020002880A
MX2020002880A MX2020002880A MX2020002880A MX2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A
Authority
MX
Mexico
Prior art keywords
antigen
antibody
binds
provides
nkg2d
Prior art date
Application number
MX2020002880A
Other languages
English (en)
Inventor
Bianka Prinz
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2020002880A publication Critical patent/MX2020002880A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se describen proteínas de unión multiespecíficas que se unen a un antígeno CLL-1 asociado con tumor, el receptor NKG2D, y CD16, así como también composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento de cáncer.
MX2020002880A 2017-09-14 2018-09-13 Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). MX2020002880A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558510P 2017-09-14 2017-09-14
PCT/US2018/050916 WO2019055677A1 (en) 2017-09-14 2018-09-13 NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1)

Publications (1)

Publication Number Publication Date
MX2020002880A true MX2020002880A (es) 2020-10-01

Family

ID=65723086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002880A MX2020002880A (es) 2017-09-14 2018-09-13 Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).

Country Status (14)

Country Link
US (1) US20200277384A1 (es)
EP (1) EP3681532A4 (es)
JP (1) JP2020534269A (es)
KR (1) KR20200051789A (es)
CN (1) CN111432832A (es)
AU (1) AU2018331412A1 (es)
BR (1) BR112020005078A2 (es)
CA (1) CA3075857A1 (es)
EA (1) EA202090718A1 (es)
IL (1) IL273206A (es)
MA (1) MA50255A (es)
MX (1) MX2020002880A (es)
SG (1) SG11202002298PA (es)
WO (1) WO2019055677A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
US20210009711A1 (en) * 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
KR20210081346A (ko) * 2018-10-19 2021-07-01 리전츠 오브 더 유니버시티 오브 미네소타 Nk 관여 분자 및 이의 사용 방법
IL297922A (en) * 2020-05-06 2023-01-01 Dragonfly Therapeutics Inc Proteins that bind nkg2d, cd16 and clec12a
US20230111279A1 (en) * 2021-04-26 2023-04-13 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
CN115850476B (zh) * 2022-08-09 2023-09-05 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115198A1 (en) * 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
JP2009500346A (ja) * 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
DK2222706T4 (en) * 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
US10865233B2 (en) * 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
CA2889681C (en) * 2012-09-27 2023-04-11 Merus B.V. Bispecific igg antibodies as t cell engagers
WO2017125897A1 (en) * 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
KR20200130514A (ko) * 2017-02-27 2020-11-18 드래곤플라이 쎄라퓨틱스, 인크. Caix, ano1, 메소텔린, trop2, cea, 또는 클라우딘-18.2를 표적화하는 다중특이적 결합 단백질

Also Published As

Publication number Publication date
AU2018331412A1 (en) 2020-03-26
US20200277384A1 (en) 2020-09-03
IL273206A (en) 2020-04-30
KR20200051789A (ko) 2020-05-13
BR112020005078A2 (pt) 2020-10-13
CN111432832A (zh) 2020-07-17
WO2019055677A1 (en) 2019-03-21
EP3681532A4 (en) 2021-09-01
EP3681532A1 (en) 2020-07-22
EA202090718A1 (ru) 2020-07-01
JP2020534269A (ja) 2020-11-26
CA3075857A1 (en) 2019-03-21
SG11202002298PA (en) 2020-04-29
MA50255A (fr) 2021-05-26

Similar Documents

Publication Publication Date Title
MX2020002880A (es) Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).
MX2020003145A (es) Nuevos complejos de polipeptidos biespecificos.
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
MX2021003436A (es) Anticuerpos humanos para pd-1.
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
EA201691858A1 (ru) Композиции антител для лечения опухолей
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
PE20170767A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2021001711A (es) Proteínas biespecíficas modificadas.
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
MX2021007093A (es) Anticuerpos btla.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022010161A (es) Proteínas biespecíficas anti-her2 diseñadas.
MX2022002524A (es) Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2020257789A3 (en) Anti-tim-3 antibodies